FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306320160> ?p ?o ?g. }

• W4306320160 abstract "Abstract Background Heart failure (HF) occurs in approximately 26% of patients with atrial fibrillation (AF). Real-world data of oral anticoagulation with edoxaban in AF patients with HF history are limited. Purpose To compare edoxaban effectiveness and safety in AF patients with or without HF history. Methods The Global ETNA-AF programme (EU: NCT02944019, Japan: UMIN000017011, South Korea/Taiwan: NCT02951039) integrates data from multiple prospective, observational, noninterventional regional studies of AF patients receiving edoxaban for stroke prevention. This snapshot analysis summarises baseline characteristics and 2-year annualised rates of all-cause death, cardiovascular (CV) death, stroke (haemorrhagic, ischaemic, any), and bleeding (major bleeding [MB], major gastrointestinal [GI] bleeding, intracranial haemorrhage [ICH], clinically relevant nonmajor bleeding [CRNMB], and any bleeding) in patients with or without HF history. Univariate Cox regression models assessed clinical outcomes. Results Data from 27,333 patients (5258 with HF history) from Europe, Japan, South Korea, and Taiwan were analysed. Patients with HF history were significantly older and had lower mean body weight and creatinine clearance (P&lt;0.0001 all; Table). Patients with HF history had significantly higher baseline stroke (CHA2DS2-VASc) and bleeding (HAS-BLED) risk scores (P&lt;0.0001 both; Table). Significantly more patients with HF history reported previous experiences with MB (P=0.001) and major GI bleeding (P=0.007); these patients were also more likely to receive 30 mg edoxaban vs 60 mg edoxaban (P&lt;0.0001; Table). Patients with HF history had significantly (P&lt;0.0001 both) higher rates of all-cause (6.1% vs 2.5%; hazard ratio [HR] (95% confidence interval [CI]), 2.41 [2.17–2.68]) and CV death (2.8% vs 1.2%; HR [95% CI], 2.39 [2.05–2.80]), and fatal bleeding (0.3% vs 0.2%; HR [95% CI], 1.86 [1.20–2.89]; Figure). The proportion of all-cause deaths that were fatal bleeding events was 6% and 7% for patients with and without HF, respectively. Additionally, patients with HF history had significantly (P&lt;0.0001 both) higher rates of MB (1.7% vs 0.9%; HR [95% CI], 1.87 [1.53–2.28]) and major GI bleeding (1.1% vs 0.4%; HR [95% CI], 2.69 [2.07–3.49]), with a greater proportion of MB events classified as major GI bleeding (64.5% vs 44.8%; P&lt;0.0001). Patients with HF history also had significantly (P&lt;0.0001 both) higher rates of CRNMB (HR [95% CI], 1.87 [1.58–2.21]) and any bleeding (HR [95% CI], 1.49 [1.34–1.65]). Rates of ICH and haemorrhagic stroke were similar in both groups. Conclusions In AF patients receiving edoxaban, the rates of MB, major GI bleeding, and CV or all-cause death were higher when comparing those with versus without HF history. The higher incidence of MB and major GI bleeding in patients with HF history did not lead to proportionally higher fatal bleeding rates among all-cause deaths. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo" @default.
• W4306320160 created "2022-10-16" @default.
• W4306320160 creator A5003379049 @default.
• W4306320160 creator A5012356817 @default.
• W4306320160 creator A5019501726 @default.
• W4306320160 creator A5041953660 @default.
• W4306320160 creator A5043373957 @default.
• W4306320160 creator A5046869520 @default.
• W4306320160 creator A5047325459 @default.
• W4306320160 creator A5052435380 @default.
• W4306320160 creator A5067459890 @default.
• W4306320160 date "2022-10-01" @default.
• W4306320160 modified "2023-09-25" @default.
• W4306320160 title "The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure" @default.
• W4306320160 doi "https://doi.org/10.1093/eurheartj/ehac544.2700" @default.
• W4306320160 hasPublicationYear "2022" @default.
• W4306320160 type Work @default.
• W4306320160 citedByCount "0" @default.
• W4306320160 crossrefType "journal-article" @default.
• W4306320160 hasAuthorship W4306320160A5003379049 @default.
• W4306320160 hasAuthorship W4306320160A5012356817 @default.
• W4306320160 hasAuthorship W4306320160A5019501726 @default.
• W4306320160 hasAuthorship W4306320160A5041953660 @default.
• W4306320160 hasAuthorship W4306320160A5043373957 @default.
• W4306320160 hasAuthorship W4306320160A5046869520 @default.
• W4306320160 hasAuthorship W4306320160A5047325459 @default.
• W4306320160 hasAuthorship W4306320160A5052435380 @default.
• W4306320160 hasAuthorship W4306320160A5067459890 @default.
• W4306320160 hasBestOaLocation W43063201601 @default.
• W4306320160 hasConcept C126322002 @default.
• W4306320160 hasConcept C127413603 @default.
• W4306320160 hasConcept C164705383 @default.
• W4306320160 hasConcept C2776301958 @default.
• W4306320160 hasConcept C2778198053 @default.
• W4306320160 hasConcept C2778810321 @default.
• W4306320160 hasConcept C2779161974 @default.
• W4306320160 hasConcept C2780290652 @default.
• W4306320160 hasConcept C2780306776 @default.
• W4306320160 hasConcept C2780645631 @default.
• W4306320160 hasConcept C71924100 @default.
• W4306320160 hasConcept C78519656 @default.
• W4306320160 hasConceptScore W4306320160C126322002 @default.
• W4306320160 hasConceptScore W4306320160C127413603 @default.
• W4306320160 hasConceptScore W4306320160C164705383 @default.
• W4306320160 hasConceptScore W4306320160C2776301958 @default.
• W4306320160 hasConceptScore W4306320160C2778198053 @default.
• W4306320160 hasConceptScore W4306320160C2778810321 @default.
• W4306320160 hasConceptScore W4306320160C2779161974 @default.
• W4306320160 hasConceptScore W4306320160C2780290652 @default.
• W4306320160 hasConceptScore W4306320160C2780306776 @default.
• W4306320160 hasConceptScore W4306320160C2780645631 @default.
• W4306320160 hasConceptScore W4306320160C71924100 @default.
• W4306320160 hasConceptScore W4306320160C78519656 @default.
• W4306320160 hasIssue "Supplement_2" @default.
• W4306320160 hasLocation W43063201601 @default.
• W4306320160 hasOpenAccess W4306320160 @default.
• W4306320160 hasPrimaryLocation W43063201601 @default.
• W4306320160 hasRelatedWork W2067977631 @default.
• W4306320160 hasRelatedWork W2073453392 @default.
• W4306320160 hasRelatedWork W2125804349 @default.
• W4306320160 hasRelatedWork W2300086221 @default.
• W4306320160 hasRelatedWork W2348720246 @default.
• W4306320160 hasRelatedWork W2886056561 @default.
• W4306320160 hasRelatedWork W2917172139 @default.
• W4306320160 hasRelatedWork W3029306217 @default.
• W4306320160 hasRelatedWork W3132289493 @default.
• W4306320160 hasRelatedWork W4200210752 @default.
• W4306320160 hasVolume "43" @default.
• W4306320160 isParatext "false" @default.
• W4306320160 isRetracted "false" @default.
• W4306320160 workType "article" @default.